. The antibody against H3.3S31ph is specific to H3.3S31ph. Immunofluorescence analysis was performed using antibodies against H3.3S31ph (green) and centromeres (human CREST antiserum; red). To validate the specificity of the anti-H3.3S31ph antibody, a H3.3S31 blocking peptide was co-incubated onto the microscope slides. (A-C) In telomerase positive A549 cells, H3.3S31ph (green) localised at the pericentric satellite DNA repeats (A) When the antibody is co-incubated with 100 ng of the H3.3S31 peptide, H3.3S31ph staining at the pericentric DNA repeats was reduced to below detection (B). The pericentric staining of H3.3S31ph was not
The staining of H3.3S31ph was not observed when 100 ng of the H3.3S31 peptide was added (E).
A low level of H3.3S31ph staining was detected on the chromosome arms when 40 ng of H3.3S31 peptide was added (F). Representative images of 50 chromosome spreads are shown. Scale bar =5µm.
Figure S2. An aberrant H3.3S31ph distribution pattern in human ALT cancer cell lines.
Immunofluorescence analysis was performed using antibodies against H3.3S31ph (green) and centromeres (human CREST antiserum; red). Immunofluorescence analysis was performed using antibodies against γH2AX (green) and centromeres (human CREST antiserum; red). W138-VA13/2RA ALT cells showed increased staining of γH2AX not only at telomeres, but also on fragmented DNA (arrowheads).
Representative images of 50 chromosome spreads were shown. Scale bar = 10µm. were arrested at G2 boundary using RO-3306. They were then released into mitosis either in the presence or absence of CHK1 inhibitor SB218078 (Chk1i) for 20 min. Immunofluorescence analysis indicated that both lines showed extremely high levels of H3.3S31ph (green) at the pericentric satellite DNA repeats and chromosome arms (A, C). Treatment of cells with CHK1 inhibitor SB218078 (Chk1i) (B, D) resulted in a significant reduction in the level of H3.3S31ph.
Centromeres were stained with a human CREST antibody (red). Representative images of 50 spreads are shown. Scale bar = 10µm. 
